Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone for multiple sclerosis in clinical practice.

Syed A Rizvi1, Howard Zwibel, Edward J Fox

  • 1Department of Clinical Neurosciences, Brown University, 2 Dudley Street, Suite 555, Providence, Rhode Island 02905, USA. srizvi@lifespan.org

Neurology
|December 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

Plasma Proteomic Networks Reveal Shared Biology with Brain Linked to Alzheimer's Disease Pathology.

medRxiv : the preprint server for health sciences·2026
Same author

Correction: Working to Increase Stability through Exercise (WISE): screening, recruitment, and baseline characteristics.

Trials·2026
Same author

Shifting Focus: An Advocacy-Focused Analysis of Omega Beta Iota's Membership and Political Engagement Strategies.

Cureus·2026
Same author

CSF Proteomics and Machine Learning Reveal Distinct Stages Across the Alzheimer's Disease Continuum.

medRxiv : the preprint server for health sciences·2025
Same author

Cerebrospinal fluid proteomics for predictive assessment of Alzheimer's Disease risk.

medRxiv : the preprint server for health sciences·2025
Same journal

Teaching Video NeuroImage: Tardive Blepharoclonus.

Neurology·2026
Same journal

Teaching NeuroImage: Latent Axonal Degeneration in Patient With Anterior Circulation Stroke.

Neurology·2026
Same journal

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same journal

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same journal

Digital Semiology.

Neurology·2026
Same journal

Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

Neurology·2026
See all related articles

Mitoxantrone can effectively treat aggressive multiple sclerosis (MS) forms, including relapsing-remitting, secondary progressive, and progressive relapsing MS. Careful patient selection and monitoring ensure safe administration and potential reduction in long-term disability.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) encompasses several progressive forms, including relapsing-remitting, secondary progressive, and progressive relapsing MS.
  • Early intervention is crucial for managing MS-related disability.
  • Mitoxantrone is an established chemotherapeutic agent with immunomodulatory properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of mitoxantrone in patients with worsening forms of multiple sclerosis.
  • To highlight the importance of early treatment initiation for mitigating long-term neurological deficits.

Main Methods:

  • Patient selection criteria focused on specific MS subtypes with active disease progression.
  • Treatment involved mitoxantrone administration with vigilant monitoring for adverse events.

Related Experiment Videos

  • Assessment of treatment outcomes included disease progression markers and adverse event incidence.

    • Main Results:

    • Mitoxantrone demonstrated potential benefits in reducing disease progression in eligible MS patients.
    • Adverse events, notably cardiotoxicity, were observed but manageable with careful monitoring.
    • The benefits of mitoxantrone for aggressive MS outweigh the risks when administered appropriately.

    Conclusions:

    • Mitoxantrone is a viable therapeutic option for patients with worsening relapsing-remitting, secondary progressive, and progressive relapsing MS.
    • Careful patient selection and proactive management of side effects are paramount for safe and effective mitoxantrone use.
    • Early and aggressive treatment with mitoxantrone may significantly impact the long-term disability trajectory in advanced MS.